MannKind and Rose Pharma Sign Worldwide Licensing Deal for Inhaled Rapid-Acting Short-Duration GLP-1 (ROSE-010) via MannKind's Technosphere Dry-Powder Platform for Weight Management
MannKind Corporation (NASDAQ: MNKD) and Rose Pharma Inc. announced Wednesday September 9, 2026 a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational rapid-acting, short-duration glucagon-like peptide-1 (GLP-1) receptor agonist peptide formulated using MannKind's proprietary Technosphere dry-powder inhalation technology for chronic weight management. Under the deal, Rose Pharma receives an exclusive worldwide license to use MannKind's Technosphere platform for ROSE-010 development and commercialization; MannKind will provide pharmaceutical development services through completion of Phase 1b and receives an equity interest in Rose Pharma, royalties on future net sales, and a board seat. Rose Pharma retains responsibility for clinical development, regulatory strategy, and commercialization. The Technosphere platform delivers peptides to the deep lung via dry-powder inhaler and previously enabled Afrezza (inhaled insulin), positioning ROSE-010 as a differentiated non-injection GLP-1 option distinct from the once-daily injectable class dominated by semaglutide and tirzepatide, or the recently launched Wegovy pill and Foundayo (orforglipron) oral small-molecule options.